Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial

@article{Romano2015RiluzoleIP,
  title={Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial},
  author={Silvia Romano and Giulia Coarelli and Christian Marcotulli and Luca Leonardi and Francesca Lo Piccolo and Maria Spadaro and Marina Frontali and Michela Ferraldeschi and Maria Chiara Vulpiani and Federica Ponzelli and Marco Salvetti and Francesco Orzi and Antonio Petrucci and Nicola Vanacore and C Casali and Giovanni Ristori},
  journal={The Lancet Neurology},
  year={2015},
  volume={14},
  pages={985-991}
}
BACKGROUND Our previous study in patients with cerebellar ataxias of different causes showed significant benefit of riluzole after 8 weeks. We aimed to confirm these results in patients with spinocerebellar ataxia or Friedreich's ataxia in a 1-year trial. METHODS Patients with spinocerebellar ataxia or Friedreich's ataxia (2:1 ratio) from three Italian neurogenetic units were enrolled in this multicentre, double-blind, placebo-controlled trial, and randomly assigned to riluzole (50 mg orally… CONTINUE READING
Highly Cited
This paper has 29 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 21 citations